D J Weisdorf

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. pmc Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis
    Daniel Weisdorf
    Department of Medicine, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin Electronic address
    Biol Blood Marrow Transplant 20:816-22. 2014
  2. pmc Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS
    S M Luger
    Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    Bone Marrow Transplant 47:203-11. 2012
  3. pmc Which donor or graft source should you choose for the strongest GVL? Is there really any difference
    Daniel Weisdorf
    Adult Blood and Marrow Transplant Program, University of Minnesota, USA Electronic address
    Best Pract Res Clin Haematol 26:293-6. 2013
  4. pmc Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research
    Armand Keating
    Princess Margaret Hospital, University of Toronto, Ontario, Canada
    Haematologica 98:185-92. 2013
  5. pmc Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning
    Daniel Weisdorf
    University of Minnesota, Division of Hematology, Oncology and Transplantation, Department of Medicine, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 18:1727-33. 2012
  6. pmc T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome
    Daniel Weisdorf
    University of Minnesota, Minneapolis, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 18:937-43. 2012
  7. pmc Should all unrelated donors for transplantation be matched?
    Daniel Weisdorf
    Blood and Marrow Transplant Program, Division of Hematology Oncology Transplant, University of Minnesota Medical School, MMC 480 PWB 14 142, 516 Delaware Street, SE, Minneapolis, MN 55455 0480, USA
    Best Pract Res Clin Haematol 21:79-83. 2008
  8. ncbi request reprint Acute radiation injury: contingency planning for triage, supportive care, and transplantation
    Daniel Weisdorf
    Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, and Department of Medicine, Bridgeport Hospital, New Haven, CT, USA
    Biol Blood Marrow Transplant 12:672-82. 2006
  9. ncbi request reprint Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review
    Daniel J Weisdorf
    University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 9:512-8. 2003
  10. pmc Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival
    Daniel Weisdorf
    University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 14:748-58. 2008

Research Grants

Collaborators

Detail Information

Publications124 found, 100 shown here

  1. pmc Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis
    Daniel Weisdorf
    Department of Medicine, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin Electronic address
    Biol Blood Marrow Transplant 20:816-22. 2014
    ..In the absence of an 8/8 HLA-matched URD or when transplantation is needed urgently, UCB can provide extended survival. Less frequent chronic GVHD with UCB transplantation may be of particular value for older patients...
  2. pmc Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS
    S M Luger
    Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    Bone Marrow Transplant 47:203-11. 2012
    ..Prospective studies comparing regimens are needed to confirm this finding and determine the optimal approach to patients who are eligible for either MA or RIC/NMA conditioning...
  3. pmc Which donor or graft source should you choose for the strongest GVL? Is there really any difference
    Daniel Weisdorf
    Adult Blood and Marrow Transplant Program, University of Minnesota, USA Electronic address
    Best Pract Res Clin Haematol 26:293-6. 2013
    ..Data on this supposition has been reviewed here to consider HLA-matched siblings, HLA-matched or partially matched unrelated donors (URD), unrelated umbilical cord blood (UCB), and haploidentical as well as blood or marrow grafts. ..
  4. pmc Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research
    Armand Keating
    Princess Margaret Hospital, University of Toronto, Ontario, Canada
    Haematologica 98:185-92. 2013
    ..In the absence of an HLA-matched sibling donor, autologous peripheral blood may provide acceptable alternative post-remission therapy for patients with acute myeloid leukemia in first complete remission...
  5. pmc Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning
    Daniel Weisdorf
    University of Minnesota, Division of Hematology, Oncology and Transplantation, Department of Medicine, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 18:1727-33. 2012
    ..After MAC, GVHD has an adverse effect on TRM with early modest augmentation of GVHD-associated graft-versus-leukemia (GVL). With RIC, GVHD-associated GVL may be important in limiting both early and late leukemia recurrence...
  6. pmc T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome
    Daniel Weisdorf
    University of Minnesota, Minneapolis, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 18:937-43. 2012
    ..Improvements in peritransplantation disease control and additional measures to augment the allogeneic graft-versus-leukemia effect are still required...
  7. pmc Should all unrelated donors for transplantation be matched?
    Daniel Weisdorf
    Blood and Marrow Transplant Program, Division of Hematology Oncology Transplant, University of Minnesota Medical School, MMC 480 PWB 14 142, 516 Delaware Street, SE, Minneapolis, MN 55455 0480, USA
    Best Pract Res Clin Haematol 21:79-83. 2008
    ..Of most significance, however, is that the best donor is HLA-compatible, healthy, promptly available, and willing to give the requested product for HCT...
  8. ncbi request reprint Acute radiation injury: contingency planning for triage, supportive care, and transplantation
    Daniel Weisdorf
    Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, and Department of Medicine, Bridgeport Hospital, New Haven, CT, USA
    Biol Blood Marrow Transplant 12:672-82. 2006
    ..The hematology/oncology community is most suited to participate in such contingency planning, and the necessary elements for its success are reviewed...
  9. ncbi request reprint Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review
    Daniel J Weisdorf
    University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 9:512-8. 2003
    ..This approach can thereby reduce investigator bias, facilitate comparison between centers, and perhaps eliminate the need for an expert PR. This technique should be used in future prospective studies of GVHD prophylaxis...
  10. pmc Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival
    Daniel Weisdorf
    University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 14:748-58. 2008
    ..This improved categorization of HLA matching status allows adjustment for donor-recipient HLA compatibility, and can standardize interpretations of prior URD HCT experience...
  11. ncbi request reprint Chronic graft-versus-host disease: where is promise for the future?
    D J Weisdorf
    1Blood and Marrow Transplantation Program, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Leukemia 19:1532-5. 2005
  12. ncbi request reprint Blood and marrow transplant clinical trials network (BMT CTN): addressing unanswered questions
    Daniel Weisdorf
    University of Minnesota, Mayo Mail Code 480, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 13:257-62; discussion 255-6. 2007
    ..The BMT CTN organizational structure, current portfolio of studies, and scientific agenda are reviewed. Opportunities for investigators in any institution to propose trials and participate are outlined...
  13. pmc Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse
    Daniel J Weisdorf
    University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 15:1475-8. 2009
    ..In this analysis, greater histoincompatibility can augment GVHD, but does not improve protection against relapse; thus the best donor remains the most closely matched donor...
  14. pmc How closely related is graft-vs-leukemia to donor/recipient disparity?
    Daniel J Weisdorf
    University of Minnesota, Minneapolis, 55455, United States
    Best Pract Res Clin Haematol 23:525-8. 2010
    ..Human leukocyte antigen (HLA) mismatch does not appear to augment the GVL effect, and increased GVHD does not necessarily lead to decreased relapse...
  15. doi request reprint Transplants for leukemia in relapse: when is the best time?
    Daniel Weisdorf
    University of Minnesota, Minneapolis, USA
    Best Pract Res Clin Haematol 24:549-52. 2011
    ..Risks of relapse may differ based on the depth of remission, measurable minimal residual disease (MRD), or patient's performance status...
  16. ncbi request reprint Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis
    J N Barker
    Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota School of Medicine, Minneapolis, MN, USA
    Blood 97:2957-61. 2001
    ..Therefore, UCB should be considered an acceptable alternative to HLA-matched BM for pediatric patients...
  17. ncbi request reprint Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer
    L J Burns
    Department of Medicine, University of Minnesota, Minneapolis 55455, USA
    Exp Hematol 28:96-103. 2000
    ..75 x 10(6) IU/m(2)/day. Fifteen women with stage IIIA/B or metastatic breast cancer underwent G-CSF mobilization alone and served as a control group...
  18. doi request reprint Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation
    Ahmed Al-Hazzouri
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 14:658-63. 2008
    ..Continuous monitoring of renal function is necessary in allogeneic HCT survivors, and studies exploring prevention strategies are needed...
  19. pmc Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome
    Michael B Tomblyn
    Department of Therapeutic Radiology and Radiation Oncology, University of Minnesota, Minneapolis, MN 55455, USA
    J Clin Oncol 27:3634-41. 2009
    ..Analysis of hematopoietic cell transplantation (HCT) for high-risk or recurrent acute lymphoblastic leukemia (ALL) using different donor sources is confounded by variable conditioning and supportive care...
  20. ncbi request reprint Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial
    M Markova
    Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis, MN, USA
    Bone Marrow Transplant 39:193-9. 2007
    ..6 (95% CI 0.2-1.3) P=0.16) and with URD RR 0.4 (0.2-1.0) P=0.04). Older patients with advanced hematologic malignancies achieve satisfactory outcomes using either of these reduced intensity conditioning regimens...
  21. pmc High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation
    J R Long-Boyle
    Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA
    Bone Marrow Transplant 46:20-6. 2011
    ..5 μg h/mL had 4.56 greater risk of TRM and significantly lower OS. These data suggest that clinical strategies are needed to optimize dosing of fludarabine to prevent overexposure and toxicity in HCT...
  22. doi request reprint Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival
    M J Burke
    Division of Hematology Oncology Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:107-13. 2009
    ..We suggest that imatinib be included in the peri-transplant management of all patients with Ph+ ALL...
  23. ncbi request reprint Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors
    S M Davies
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis 55455, USA
    Am J Med 110:339-46. 2001
    ....
  24. ncbi request reprint Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units
    C G Brunstein
    University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:935-40. 2009
    ..Survival was 47% at 1 year. Despite safety of administration, IBMI of one of two UCB units did not shorten the time to neutrophil engraftment and offers no advantage over conventional double unit transplantation...
  25. pmc Impact of ABO-mismatch on risk of GVHD after umbilical cord blood transplantation
    R Romee
    Medicine, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 48:1046-9. 2013
    ..Whereas ABO-compatible donors are preferred in recipients of URD-HCT, ABO compatibility generally need not be considered in recipients of UCB-HCT. ..
  26. pmc Factors predicting single-unit predominance after double umbilical cord blood transplantation
    P Ramirez
    Department of Medicine, University of Minnesota, Blood and Marrow Transplant Program, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 47:799-803. 2012
    ..4; P=0.05) were independent factors associated with unit predominance. Taken together, these findings suggest that immune reactivity has a role in unit predominance, and should be considered during graft selection and graft manipulation...
  27. ncbi request reprint Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens
    A Al-Hazzouri
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:949-51. 2009
    ..6 vs RIC). At least in the first few years after HCT, the risks for hypothyroidism are similar among patients receiving TBI-based MA and reduced-intensity regimens...
  28. ncbi request reprint Unrelated donor bone marrow transplantation for children with acute leukemia
    S M Davies
    Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA
    J Clin Oncol 15:557-65. 1997
    ..To test the use of unrelated donor bone marrow transplantation (URD BMT) to cure children with high-risk acute leukemias...
  29. doi request reprint Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma
    V Bachanova
    Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:237-44. 2009
    ....
  30. ncbi request reprint Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma
    M Arora
    Division of Hematology, Oncology and Transplantation, Department of Medicine, and the Blood and Marrow Transplant Program, University of Minnesota, MN 55455, USA
    Bone Marrow Transplant 35:1133-40. 2005
    ..Allogeneic HCT may be suitable in younger patients, soon after diagnosis, and in those with chemosensitive disease...
  31. ncbi request reprint Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer
    L J Burns
    Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Exp Hematol 28:352. 2000
    ....
  32. pmc Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors
    N S Majhail
    Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 47:494-8. 2012
    ..UCB is feasible as an alternative donor source for reduced-intensity conditioning HCT among older patients with AML and MDS who do not have a suitable MSD...
  33. ncbi request reprint Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma
    Navneet S Majhail
    Blood and Marrow Transplant Program, Division of Medical and Pediatric Hematology, University of Minnesota, Minneapolis, 55455, USA
    Blood 107:3804-7. 2006
    ..67). Our results suggest comparable outcomes for reduced-intensity allo-SCT using UCB or MSD in adults at high risk with advanced Hodgkin lymphoma...
  34. doi request reprint New classification of chronic GVHD: added clarity from the consensus diagnoses
    M Arora
    Blood and Marrow Transplant Program, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:149-53. 2009
    ..1% (95% CI 68-94)); P=0.1. This analysis, undertaken in a contemporary cohort of related donor recipients, indicates that the consensus guidelines are applicable to this population of CGVHD patients...
  35. ncbi request reprint Alveolar hemorrhage following allogeneic hematopoietic cell transplantation using reduced-intensity conditioning
    N S Majhail
    Blood and Marrow Transplant Program, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 38:765-8. 2006
    ..Reducing the intensity of preparative regimen does not protect against post transplant alveolar hemorrhage. Alveolar hemorrhage occurring after RIC or MAC HCT has similar incidence, clinical presentation, and associated high mortality...
  36. ncbi request reprint Cytomegalovirus enteritis among hematopoietic stem cell transplant recipients
    J A van Burik
    Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, USA
    Biol Blood Marrow Transplant 7:674-9. 2001
    ..Viremia was detected in two thirds of patients with CMV prior to the diagnosis of enteritis. Most treatment regimens included ganciclovir. The overall survival rate was 35% at 2 years following the onset of enteritis...
  37. ncbi request reprint A modified comorbidity index for hematopoietic cell transplantation
    T E DeFor
    Biostatistics and Informatics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 45:933-8. 2010
    ..In conclusion, we are introducing the MCI which may have higher discriminating and predictive power for overall survival and NRM. Validation of the HCT-CI and the MCI in larger and separate cohorts of HCT recipients is still needed...
  38. pmc KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation
    Sarah Cooley
    Division of Hematology Oncology and Transplantation, University of Minnesota Cancer Center, University of Minnesota, National Marrow Donor Program, MMC 806, Harvard St at E River Rd, Minneapolis, MN 55455, USA
    Blood 106:4370-6. 2005
    ..These results support the notion that T cells in the graft affect NK cell reconstitution in vivo. Understanding these mechanisms may result in strategies to improve clinical outcomes from unrelated HCT...
  39. ncbi request reprint Infections during mobilizing chemotherapy and following autologous stem cell transplantation
    A A Toor
    Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 28:1129-34. 2001
    ..However, although post-transplant neutropenia is brief, infections remain a significant cause of morbidity...
  40. doi request reprint Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients
    M J Burke
    University of Minnesota, Minneapolis, 55455, USA
    Bone Marrow Transplant 44:169-74. 2009
    ..44). Thus, patients treated with imatinib either before or after myeloablative allo-HCT had no increase in cardiac toxicity...
  41. ncbi request reprint Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma
    M Tomblyn
    Blood and Marrow Transplant Program, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 40:111-8. 2007
    ..The poor clinical outcome of patients with difficult mobilization using either method identifies them as a high-risk group who might benefit from alternative therapies...
  42. ncbi request reprint The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission
    Rachel E Lerner
    Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 13:486-92. 2007
    ..These results suggest that the IPI-R predicts OS and PFS following auto HSCT for patients with aggressive NHL in CR 2 or PR 2. Patients with high-risk IPI-R should be considered for novel therapeutic approaches...
  43. ncbi request reprint Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources
    Christopher M Walker
    Division of Infectious Diseases, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455 0250, USA
    Biol Blood Marrow Transplant 13:1106-15. 2007
    ..Recipients of UCB have similar risks of CMV infection, responses to antiviral therapy, and survival following CMV infection as recipients of either marrow or PBSC...
  44. doi request reprint Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival
    Priya Kumar
    Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 14:1394-400. 2008
    ..4, 95% CI, 0.2-0.6, P < .01). When compared with URD:M, OS with UCB was better (RR 0.3, 95% CI, 0.1-0.7, P = .01), supporting the use of UCB as an alternative stem cell source for adults with ALL...
  45. ncbi request reprint Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma
    Navneet S Majhail
    Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 12:1065-72. 2006
    ..A risk-adapted approach should be followed in determining treatment options for patients with PR REF and REL HL...
  46. pmc Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease
    V Bachanova
    Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN, USA
    Leukemia 28:658-65. 2014
    ..88; P=0.018), RIC (HR 1.891; P=0.054) and pre-HCT MRD(pos) (HR 1.6; P=0.070) increased relapse risk. RIC is a valid alternative strategy for Ph+ ALL patients ineligible for MAC and MRD(neg) status is preferred pre-HCT. ..
  47. ncbi request reprint Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients
    J N Barker
    University of Minnesota Medical School, Minneapolis, USA
    Biol Blood Marrow Transplant 7:395-9. 2001
    ..Because adoptive immunotherapy with donor lymphocytes is not an available option for recipients of unrelated-donor UCBT, new therapeutic strategies are needed, and rituximab appears promising...
  48. ncbi request reprint Chronic graft-versus-host disease: a prospective cohort study
    Mukta Arora
    Department of Medicine, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 9:38-45. 2003
    ..Recognition of a high-risk group should facilitate assignment of more intensified regimens. Better treatment regimens need to be identified to improve survival and limit toxicity of prolonged immunosuppression...
  49. pmc Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity
    Claudio G Brunstein
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 113:5628-34. 2009
    ..8; 95% CI, 1.0-3.1; P = .05). Our results do not support the selection of UCB units based on KIR-L status and suggest that KIR-L mismatching should be avoided in reduced intensity UCB transplantation...
  50. ncbi request reprint Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation
    Elena G Chiorean
    Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 10:171-7. 2004
    ....
  51. ncbi request reprint Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997
    T Murdych
    Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Bone Marrow Transplant 28:283-7. 2001
    ..These data suggest that with appropriate pre-transplant clinical evaluation, high-dose cyclophosphamide and irradiation in the BMT preparative phase does not result in frequent, clinically relevant short-term cardiac toxicity...
  52. ncbi request reprint Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma
    Mukta Arora
    Department of Medicine, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 10:395-404. 2004
    ..Two cycles of priming chemotherapy plus autologous transplantation yields survival rates similar to those in published reports, including those using tandem transplantation...
  53. pmc Higher therapeutic CsA levels early post transplantation reduce risk of acute GVHD and improves survival
    J R Rogosheske
    University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN, USA
    Bone Marrow Transplant 49:122-5. 2014
    ..In patients who are near or even modestly above the CsA target trough level, in the absence of CsA-related toxicity, dose reduction should be cautious to avoid subtherapeutic drug levels resulting in higher risk of acute GVHD. ..
  54. pmc Association between genetic variants in adhesion molecules and outcomes after hematopoietic cell transplants
    B Thyagarajan
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
    Int J Immunogenet 40:108-15. 2013
    ..02). None of the SNPs were associated with acute or chronic GvHD risk. These findings suggest that genetic variants in the vascular adhesion molecules may be used to identify patients at high risk for TRM...
  55. doi request reprint Future of cord blood for oncology uses
    C G Brunstein
    Division of Hematology, Oncology and Transplantation, Department of Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 44:699-707. 2009
    ..We review here the background data on the utilization of UCB for the treatment of hematological malignancies, and discuss the current challenges and future directions in the field of UCB transplantation...
  56. ncbi request reprint Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation
    L J Burns
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 30:945-51. 2002
    ....
  57. ncbi request reprint Pneumocystis carinii pneumonitis following bone marrow transplantation
    I Z Tuan
    Department of Medicine, University of Minnesota, Minneapolis
    Bone Marrow Transplant 10:267-72. 1992
    ..Ongoing immunocompromise and need for prophylaxis should be appreciated in patients with graft-versus-host disease.(ABSTRACT TRUNCATED AT 250 WORDS)..
  58. pmc Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia
    Sarah Cooley
    University of Minnesota, Minneapolis, USA
    Blood 113:726-32. 2009
    ..KIR genotyping of prospective donors, in addition to HLA typing, should be performed to identify HLA-matched donors with B KIR haplotypes...
  59. ncbi request reprint Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants
    Navneet S Majhail
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 14:985-92. 2008
    ..The HCT-CI, although a useful tool for capturing pretransplant comorbidity and risk-assessment, needs to be further validated prior to adopting it for routine clinical use...
  60. pmc HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia
    Mukta Arora
    University of Minnesota, National Marrow Donor Program, Center for International Blood and Marrow Transplant Research, Minneapolis, MN 55455, USA
    J Clin Oncol 27:1644-52. 2009
    ..However, the utility and outcome associated with transplants from URDs compared with those from MSDs remains undefined...
  61. pmc Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation
    Marcie Tomblyn
    Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 14:538-45. 2008
    ..Modifications to refine patient assignment to the preferred conditioning intensity and reduce relapse risks with NMA approaches are needed...
  62. pmc Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors
    Margaret L Macmillan
    Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Blood 113:2410-5. 2009
    ..This study is registered at (http://www.clinicaltrials.gov) under the identifiers NCT00305682 and NCT00309842...
  63. pmc Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood
    Claudio G Brunstein
    University of Minnesota Medical Center, Minneapolis, MN, USA
    Blood 116:4693-9. 2010
    ..For patients without an available HLA matched donor, the use of 2 partially HLA-matched UCB units is a suitable alternative...
  64. pmc Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units
    Michael R Verneris
    Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Blood 114:4293-9. 2009
    ..This trial was registered at http://clinicaltrials.gov as NCT00309842...
  65. pmc Costs of pediatric allogeneic hematopoietic-cell transplantation
    Navneet S Majhail
    Adult Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Pediatr Blood Cancer 54:138-43. 2010
    ..Allogeneic hematopoietic-cell transplantation (HCT), although curative for some high-risk diseases, is a complex and costly procedure. The costs of transplantation among children have not been described previously...
  66. doi request reprint Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications
    Navneet S Majhail
    University of Minnesota, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 15:564-73. 2009
    ..These costs are primarily driven by severe posttransplant complications, graft failure, and prolonged inpatient stay. Strategies to enhance engraftment will decrease the costs of UCB transplantation...
  67. pmc Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation
    Anne H Blaes
    University of Minnesota Blood and Marrow Transplant Program, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 16:287-91. 2010
    ....
  68. doi request reprint Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care?
    Brian L McClune
    University of Minnesota, Minneapolis, Minnesota, USA
    Curr Opin Hematol 17:133-8. 2010
    ..We reviewed reduced-intensity hematopoietic cell transplantation for older patients in the context of recently published studies...
  69. doi request reprint The best endpoint for acute GVHD treatment trials
    Margaret L Macmillan
    Blood and Marrow Transplant Program, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Blood 115:5412-7. 2010
    ..No other differences in response by donor source were observed. These data suggest that day 28 is the best early endpoint for acute GVHD therapeutic trials in predicting 2-year TRM...
  70. pmc Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome
    Brian L McClune
    DO, University of Minnesota, Division of Hematology, Oncology and Transplantation, University of Minnesota, MMC 480, 420 Delaware St SE, Minneapolis, MN 55455, USA
    J Clin Oncol 28:1878-87. 2010
    ..Better pre-HCT performance status predicted improved 2-year OS. CONCLUSION With these similar outcomes observed in older patients, we conclude that older age alone should not be considered a contraindication to HCT...
  71. pmc Association between genetic variants in the base excision repair pathway and outcomes after hematopoietic cell transplantations
    Bharat Thyagarajan
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 16:1084-9. 2010
    ..These findings suggest that SNPs in the BER pathway can be used as genetic biomarkers to predict individuals at high risk for TRM and disease relapse. Modulation of pretransplant conditioning may alter risk in these patients...
  72. doi request reprint Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation
    Veronika Bachanova
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 113:2902-5. 2009
    ..01). For adults with ALL in CR, reduced intensity conditioning allografting results in modest TRM, limited risk of relapse, and promising leukemia-free survival. Clinical trial numbers are NCT00365287, NCT00305682, and NCT00303719...
  73. pmc Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia
    Sarah Cooley
    Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 116:2411-9. 2010
    ..Adopting this practice could result in superior disease-free survival for patients with AML...
  74. doi request reprint Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation
    Claudio G Brunstein
    University of Minnesota Blood and Marrow Transplant Program, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 15:214-22. 2009
    ..Based on our data, we conclude that a nonmyeloablative conditioning regimen followed by UCB transplantation is an effective treatment for patients with advanced lymphoid malignancies who lack a suitable sibling donor...
  75. pmc Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor
    Navneet S Majhail
    Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 14:282-9. 2008
    ..A careful review of existing comorbidities is necessary when considering older patients for HCT...
  76. ncbi request reprint A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease
    Margaret L Macmillan
    Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 109:2657-62. 2007
    ..This prospective, multicenter, randomized clinical trial for steroid-resistant acute GVHD serves as a model for future evaluation of new agents...
  77. ncbi request reprint Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults
    Juliet N Barker
    The University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN 55455, USA
    Br J Haematol 118:101-7. 2002
    ..Future efforts should focus on improving the outcome for older BMT recipients, especially those with diagnoses other than CML...
  78. ncbi request reprint Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor
    Stella M Davies
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis 55455, USA
    Blood 100:3825-7. 2002
    ..It is possible that there will be a benefit of NK cell alloreactivity if strategies of haploidentical transplantation are used: high stem cell doses, extensive T-cell depletion, and no postgrafting immune suppression...
  79. ncbi request reprint Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States
    K Scott Baker
    Pediatric Blood and Marrow Transplant Program, University of Minnesota, Mayo Mail Code 484, Minneapolis, MN 55455, USA
    J Clin Oncol 23:7032-42. 2005
    ..The purpose of this study was to examine the relationship between ethnicity and post-transplantation events and determine their net effect on survival...
  80. ncbi request reprint Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
    Jeffrey S Miller
    Division Medical and Pediatric Hematology Oncology, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Blood 105:3051-7. 2005
    ..These findings suggest that haploidentical NK cells can persist and expand in vivo and may have a role in the treatment of selected malignancies used alone or as an adjunct to HCT...
  81. ncbi request reprint Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy
    Juliet N Barker
    Blood and Marrow Transplant Program, Division of Medical and Pediatric Oncology, University of Minnesota, Box 480, 420 Delaware St SE, Minneapolis, MN 55455, USA
    Blood 105:1343-7. 2005
    ..Therefore, transplantation of 2 partially HLA-matched UCB units is safe, and may overcome the cell-dose barrier that limits the use of UCB in many adults and adolescents...
  82. ncbi request reprint Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems
    Margaret L Macmillan
    Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 8:387-94. 2002
    ..More effective prophylaxis and therapy for acute GVHD is needed for mismatched unrelated donor recipients and for those with severe GVHD...
  83. ncbi request reprint Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study
    K Scott Baker
    University of Minnesota Cancer Center, Blood and Marrow Transplant Program, Department of Internal Medicine, University of Minnesota, Minneapolis, USA
    Blood 104:1898-906. 2004
    ..However, adverse medical late effects with significant morbidity were uncommon. Chronic GVHD is the most important predictor of adverse medical late effects and poor overall health...
  84. ncbi request reprint High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation
    Margaret L Macmillan
    Department of Pediatrics, University of Minnesota, MMC 484, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Transplantation 76:1758-62. 2003
    ..Because IL-2 is a proinflammatory cytokine, we hypothesized that recipients with high-producer genotypes would have increased frequency of GVHD after allogeneic bone marrow transplantation (BMT)...
  85. ncbi request reprint Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes
    Arkadiusz Z Dudek
    Bone Marrow Transplantation Program, University of Minnesota Health Sciences Center, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 9:657-66. 2003
    ..BrOb had high mortality rate of 55%, and pulmonary failure was the leading cause of death. More effective BrOb therapy is needed, especially for patients with unfavorable presentation...
  86. ncbi request reprint Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival
    John E Wagner
    Blood and Marrow Transplant Program of the Department of Pediatrics, University of Minnesota Cancer Center and School of Medicine, Minneapolis 55455, USA
    Blood 100:1611-8. 2002
    ..7 x 10(5) CD34(+) cells per kilogram of recipient's body weight. Therefore, graft selection should be based principally on CD34 cell dose when multiple UCB units exist with an HLA disparity of 2 or less...
  87. ncbi request reprint Interleukin-1 genotype and outcome of unrelated donor bone marrow transplantation
    Margaret L Macmillan
    Pediatrics Department, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Br J Haematol 121:597-604. 2003
    ..2, P < 0.01) and decreased TRM (RR 0.1, P < 0.01). These data suggest that donor polymorphism in IL-1alpha and IL-1beta might influence survival after unrelated donor BMT, but does not alter risk of GVHD...
  88. ncbi request reprint Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning
    Juliet N Barker
    Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN, USA
    Blood 102:1915-9. 2003
    ..These data demonstrate that 0-2 antigen mismatched UCB is sufficient to engraft most adults after reduced-intensity conditioning and is associated with a low incidence of severe acute GVHD...
  89. pmc Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation
    Claudio G Brunstein
    Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Blood 108:2874-80. 2006
    ..Use of ATG in recipients of an NMA preparative regimen warrants close monitoring for evidence of EBV reactivation and potentially preemptive therapy with rituximab...
  90. pmc Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)
    Bruce R Blazar
    Cancer Center, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 55455, USA
    Blood 108:3216-22. 2006
    ..We conclude that palifermin was generally safe in allogeneic HSCTs but had no significant effect on engraftment, acute GVHD, or survival in this trial...
  91. ncbi request reprint Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes
    Navneet S Majhail
    Blood and Marrow Transplant Program, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 12:1038-46. 2006
    ..28). The pathogenesis of alveolar hemorrhage after HSCT is multifactorial, and we propose that IAH and DAH in HSCT recipients are related clinical syndromes with similar clinical presentation, risks, and associated high mortality...
  92. ncbi request reprint Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease
    Margaret L Macmillan
    Department of Pediatrics, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 8:40-6. 2002
    ..These data suggest that treatment with ATG can be an active therapy, especially in patients with skin GVHD and early signs of steroid resistance...
  93. ncbi request reprint Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB)
    Mukta Arora
    Blood and Marrow Transplant Program, Departments of Medicine and Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 13:1145-52. 2007
    ..In addition, progressive onset of cGVHD was a significant predictor of increased mortality in URD cohort. These data suggest that cGVHD following UCB transplant may be more responsive to therapy and also lead to a lower NRM...
  94. ncbi request reprint Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation
    Daniel J Weisdorf
    University of Minnesota Mayo Mail Code 480, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Blood 99:1971-7. 2002
    ..Improvements in URD and MSD transplantation are still needed, and results of newer, nontransplantation therapies should be evaluated against the established curative potential of URD and MSD marrow transplantation...
  95. ncbi request reprint A randomized trial of the effect of a walking regimen on the functional status of 100 adult allogeneic donor hematopoietic cell transplant patients
    Todd E DeFor
    Blood and Marrow Transplant Program of the Department of Pediatrics, University of Minnesota, Cancer Center and School of Medicine, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 13:948-55. 2007
    ..Structured exercise may have a positive impact on physical and emotional recovery following transplant therapy and may accelerate patients' return to health and function...
  96. pmc Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone
    Jeffrey S Miller
    Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Blood 110:2761-3. 2007
    ..This trial was registered at www.clinicaltrials.gov as no. NCT00303693 and www.cancer.gov/clinicaltrials as no. NCT00167180...
  97. pmc Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease
    Claudio G Brunstein
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis MN, USA
    Blood 110:3064-70. 2007
    ..01) and use of 2 UCB units (P = .07). These findings support the use of UCB after a nonmyeloablative conditioning as a strategy for extending the availability of transplantation therapy, particularly for older patients...
  98. ncbi request reprint Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow
    Juliet N Barker
    Department of Medicine, University of Minnesota School of Medicine, Minneapolis, USA
    Biol Blood Marrow Transplant 8:257-60. 2002
    ..These unique features of UCB transplantation must be considered in comparisons of the outcomes of UCB versus BM transplant recipients and in the design of prospective trials comparing URD sources...
  99. pmc Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT
    Jeffery S Miller
    Divisions of Adult and Pediatric Hematology, Oncology and Transplantation, University of Minnesota Cancer Center, Harvard Street at East River Road, Minneapolis, MN 55455, USA
    Blood 109:5058-61. 2007
    ..58, 95% CI 1.13-2.22; P = .008). These data support a genetically determined role for NK cells following unrelated HCT in myeloid leukemia...
  100. ncbi request reprint Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience
    David H McKenna
    Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota Medical School, Minnesota 55108, USA
    Transfusion 47:520-8. 2007
    ..Herein is a report on the experience of clinical-scale, good manufacturing practices (GMPs) production of NK cells to treat advanced cancer...
  101. ncbi request reprint IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial
    L J Burns
    Blood and Marrow Transplant Program and Cancer Center, University of Minnesota, Mayo Mail Code 286, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 32:177-86. 2003
    ..With this dose and schedule of administration of IL-2, no improvement in patient disease outcomes was noted. Alternative strategies will be needed to exploit the immunotherapeutic potential of IL-2-activated NK cells...

Research Grants2

  1. Enhanced GVHD Prophylaxis in Allogeneic Stem Cell Transplantation
    Daniel Weisdorf; Fiscal Year: 2007
    ..End of abstract.) ..